Literature DB >> 18305215

Structural and numerical variation of FLT3/ITD in pediatric AML.

Soheil Meshinchi1, Derek L Stirewalt, Todd A Alonzo, Titus J Boggon, Robert B Gerbing, Jennifer L Rocnik, Beverly J Lange, D Gary Gilliland, Jerald P Radich.   

Abstract

FLT3 internal tandem duplication (FLT3/ITD) is a common somatic mutation in acute myeloid leukemia (AML) with significant variation in the position, length, and number of duplications of the FLT3 gene. We evaluated these physical characteristics in FLT3/ITD-positive patients who were treated on CCG-2941/2961 and correlated them with clinical outcome. Fiftynine of 77 FLT3/ITD-positive patients (77%) had a single ITD, 16 (21%) had 2 ITDs, and 2 (3%) had 3 ITDs. The length of the duplicated region varied from 6 to 51 amino acids, and in all cases amino acid residues Y591-Y597 were duplicated. Structural analysis demonstrated that Y591-Y597 encodes the switch and zipper regions of the juxtamembrane domain of FLT3. In addition, 24 of 77 patients (31%) had duplication of the critical STAT5 docking sites Y589/591. Patients with longer ITDs had a worse relapse-free survival (19% vs 51%, P = .035), while the presence of more than 1 ITD was not clinically significant. Physical characteristics including the length of FLT3/ITD may influence FLT3 activation state by altering its structure and may impact response to therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305215      PMCID: PMC2384125          DOI: 10.1182/blood-2008-01-117770

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Authors:  H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

3.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.

Authors:  S Meshinchi; W G Woods; D L Stirewalt; D A Sweetser; J D Buckley; T K Tjoa; I D Bernstein; J P Radich
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

5.  Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia.

Authors:  Soheil Meshinchi; Derek L Stirewalt; Todd A Alonzo; Quangeng Zhang; David A Sweetser; William G Woods; Irwin D Bernstein; Robert J Arceci; Jerald P Radich
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

6.  FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

Authors:  D L Stirewalt; K J Kopecky; S Meshinchi; F R Appelbaum; M L Slovak; C L Willman; J P Radich
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

7.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

8.  CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.

Authors:  Stefan Fröhling; Richard F Schlenk; Ina Stolze; Jörg Bihlmayr; Axel Benner; Sylvia Kreitmeier; Karen Tobis; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

9.  The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.

Authors:  James Griffith; James Black; Carlos Faerman; Lora Swenson; Michael Wynn; Fan Lu; Judith Lippke; Kumkum Saxena
Journal:  Mol Cell       Date:  2004-01-30       Impact factor: 17.970

10.  FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.

Authors:  Christian M Zwaan; Soheil Meshinchi; Jerald P Radich; Anjo J P Veerman; Dieuwke R Huismans; Leonhard Munske; Martina Podleschny; Karel Hählen; Rob Pieters; Martin Zimmermann; Dirk Reinhardt; Jochen Harbott; Ursula Creutzig; Gertjan J L Kaspers; Frank Griesinger
Journal:  Blood       Date:  2003-06-19       Impact factor: 22.113

View more
  35 in total

1.  Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia.

Authors:  Amy L Paguirigan; Jordan Smith; Soheil Meshinchi; Martin Carroll; Carlo Maley; Jerald P Radich
Journal:  Sci Transl Med       Date:  2015-04-01       Impact factor: 17.956

2.  Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features.

Authors:  Pradeep S Chauhan; Bharat Bhushan; Ashwani K Mishra; Laishram C Singh; Sumita Saluja; Saurabh Verma; Dipendra K Gupta; Vishakha Mittal; Sumita Chaudhry; Sujala Kapur
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

3.  Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia.

Authors:  Mike Fischer; Ulf Schnetzke; Bärbel Spies-Weisshart; Mario Walther; Maximilian Fleischmann; Inken Hilgendorf; Andreas Hochhaus; Sebastian Scholl
Journal:  Haematologica       Date:  2016-12-29       Impact factor: 9.941

4.  Impact of FLT3-ITD length on prognosis of acute myeloid leukemia.

Authors:  Song-Bai Liu; Hao-Jie Dong; Xie-Bing Bao; Qiao-Cheng Qiu; Hong-Zhi Li; Hong-Jie Shen; Zi-Xuan Ding; Chao Wang; Xiao-Ling Chu; Jing-Qiu Yu; Tao Tao; Zheng Li; Xiao-Wen Tang; Su-Ning Chen; De-Pei Wu; Ling Li; Sheng-Li Xue
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

5.  Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.

Authors:  E Manara; G Basso; M Zampini; B Buldini; C Tregnago; R Rondelli; R Masetti; V Bisio; M Frison; K Polato; G Cazzaniga; G Menna; F Fagioli; P Merli; A Biondi; A Pession; F Locatelli; M Pigazzi
Journal:  Leukemia       Date:  2016-06-28       Impact factor: 11.528

6.  Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.

Authors:  Gautam Borthakur; Hagop Kantarjian; Keyur P Patel; Farhad Ravandi; Wei Qiao; Stefan Faderl; Tapan Kadia; Raja Luthra; Sherry Pierce; Jorge E Cortes
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

Review 7.  The role of molecular tests in acute myelogenous leukemia treatment decisions.

Authors:  Gabriela Motyckova; Richard M Stone
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 8.  Minimal residual disease quantitation in acute myeloid leukemia.

Authors:  David Shook; Elaine Coustan-Smith; Raul C Ribeiro; Jeffrey E Rubnitz; Dario Campana
Journal:  Clin Lymphoma Myeloma       Date:  2009

9.  Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Authors:  David B Rosen; Mark D Minden; Steven M Kornblau; Aileen Cohen; Urte Gayko; Santosh Putta; John Woronicz; Erik Evensen; Wendy J Fantl; Alessandra Cesano
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

10.  Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

Authors:  Hiroto Inaba; Elaine Coustan-Smith; Xueyuan Cao; Stanley B Pounds; Sheila A Shurtleff; Kathleen Y Wang; Susana C Raimondi; Mihaela Onciu; Jeffrey Jacobsen; Raul C Ribeiro; Gary V Dahl; W Paul Bowman; Jeffrey W Taub; Barbara Degar; Wing Leung; James R Downing; Ching-Hon Pui; Jeffrey E Rubnitz; Dario Campana
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.